| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/02/2023 | 16:07 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 01/09/2022 | 14:39 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(g) (15-12g) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 29/08/2022 | 18:31 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 29/08/2022 | 18:10 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 23/08/2022 | 23:01 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 22/08/2022 | 15:32 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 22/08/2022 | 15:22 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 22/08/2022 | 15:20 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 22/08/2022 | 15:09 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 22/08/2022 | 14:55 | Business Wire | Innoviva Completes Acquisition of La Jolla Pharmaceutical | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 15/08/2022 | 14:04 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 25/07/2022 | 14:40 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 25/07/2022 | 14:35 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 12/07/2022 | 12:10 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 11/07/2022 | 21:47 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 11/07/2022 | 13:32 | Business Wire | Innoviva to Acquire La Jolla Pharmaceutical Company | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 05/07/2022 | 23:52 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 16/05/2022 | 22:15 | Business Wire | La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 09/03/2022 | 14:15 | Business Wire | La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 09/03/2022 | 14:02 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 17/11/2021 | 14:00 | Business Wire | La Jolla Pharmaceutical Company Announces Share Repurchase Plan | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 04/11/2021 | 13:45 | Business Wire | La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 02/11/2021 | 14:14 | Edgar (US Regulatory) | Notification That a Class of Securities of Successor Issuer Is Demed to Be Registered Pursuant to Section 12(b) (8-k12b) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 10/09/2021 | 14:00 | Business Wire | Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 05/08/2021 | 14:30 | Business Wire | La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 04/06/2021 | 13:16 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 04/06/2021 | 13:06 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 25/05/2021 | 23:06 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 07/05/2021 | 14:45 | Business Wire | La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 & Highlights Corporate ... | NASDAQ:LJPC | La Jolla Pharmaceutical Company |
| 08/03/2021 | 14:55 | Business Wire | La Jolla Pharmaceutical Company Announces Financial Results for the Three & Twelve Months Ended December 31, 2020 & Highlight... | NASDAQ:LJPC | La Jolla Pharmaceutical Company |